References
- Yip S-K, Leung T-N, Fung HYM. Exposure to angiotensin-converting enzyme inhibitors during first trimester: Is it safe to fetus? Acta Obstet Gynecol Scand 1998; 77: 570–1.
- Rigó J, Gláz E, Papp Z. Low or high doses of spironolactone for treatment of maternal Bartter’s syndrome. Am J Obstet Gynecol 1996; 174: 297.
- Brent RL, Beckmann DA. Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clinical teratology counsellors. Teratology 1991; 43: 543–6.
References
- Barr M Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994; 50: 399–409.
- Hanssens M, Keirse MJNC, Vankelecom F, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991; 78: 128–35.
- Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: Experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994; 96: 451–6.